Literature DB >> 27546709

The ABC Method and Gastric Cancer: Evidence From Prospective Studies.

Shizuka Sasazuki1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27546709      PMCID: PMC5121428          DOI: 10.2188/jea.JE20160140

Source DB:  PubMed          Journal:  J Epidemiol        ISSN: 0917-5040            Impact factor:   3.211


× No keyword cloud information.
In this issue, Ikeda et al[1] reported on the predictive ability of the combination of Helicobacter pylori (H. pylori) antibody and serum pepsinogen (sPG), known as the ABC method, for gastric cancer occurrence in a long-term prospective study. The Hisayama Study is known for its long follow-up period and high rates of medical examinations, autopsies, and follow-up. The most important finding in this report is that adding sPG further improved the accuracy and discriminatory ability of the risk prediction model of developing gastric cancer compared with H. pylori alone. Based on several evaluation indices, Ikeda et al concluded that the combination of H. pylori and sPG is a significant predictor for the development of gastric cancer over a long-term period. It is also notable that the authors ultimately combined Group C (positive for H. pylori antibodies and sPG) and Group D (negative for H. pylori antibodies and positive for sPG) because there was no significant difference in the cumulative incidence of gastric cancer in these groups. Similar findings were observed in a recent meta-analysis of prospective studies in Eastern Asians[2]: compared to Group A, the summary hazard ratios for developing gastric cancer for Groups B, C, and D were 2.50 (95% confidence interval [CI], 1.24–4.51), 10.00 (95% CI, 5.20–17.51), and 15.00 (95% CI, 7.50–27.11), respectively. When compared to Group C, the summary estimate for Group D was 1.56 (95% CI, 0.84–2.65). Based on a sample of almost 20 000 individuals from the Japan Public Health Center-based prospective study (the JPHC Study), Charvat et al observed a similar pattern. The corresponding hazard ratios were 7.58 (95% CI, 4.16–13.79), 13.86 (95% CI, 7.76–24.75), and 14.09 (95% CI, 7.03–28.26) for Groups B, C, and D, respectively.[3] Using the model developed based on the ABC method and lifestyle factors, estimates of the 10-year probability of gastric cancer occurrence ranged from 0.04% (95% CI, 0.02%–0.10%) to 14.87% (95% CI, 8.96%–24.14%) for men and from 0.03% (95% CI, 0.02%–0.07%) to 4.91% (95% CI, 2.71%–8.81%) for women.[3] A risk prediction model is a simple and effective method for evaluating individualized risk by quantifying cancer risk. In the era of personalized medicine, prediction models are expected to play a role in screening for high-risk groups, assisting medical decision-making and health education, and so on. The combination of H. pylori and sPG is expected to be an effective tool for determining gastric cancer risk.[4] The findings of Ikeda et al in this issue provide further evidence that the method can stratify middle-aged healthy adults by gastric cancer risk. The proportion of participants categorized as Groups A, B, C, and D was 25%, 46%, 26%, and 3% in the Hisayama Study and 29%, 30%, 38%, and 3% in the JPHC Study, respectively. Although the prevalence of H. pylori positivity has been declining in Japan in recent years, the proportion in Groups B, C, and D might still be relatively high. Therefore, it is conceivably difficult to use the ABC method as the primary screening method in Japan. This method has been introduced in some gastric cancer primary screening settings in Japan, but how to use this method in the real world has not yet been established. These preventive measures could be used to assist in choosing subjects for gastric cancer screening (eg, when, who, and how frequently). In addition, it may provide an incentive for individuals to undergo clinical examinations earlier when they become aware of the symptoms. The next step in this research might be to clarify the role of the ABC method by aggregating data and exploring how to apply this method to the real world by monitoring existing cumulative data.
  4 in total

1.  Prediction of the 10-year probability of gastric cancer occurrence in the Japanese population: the JPHC study cohort II.

Authors:  Hadrien Charvat; Shizuka Sasazuki; Manami Inoue; Motoki Iwasaki; Norie Sawada; Taichi Shimazu; Taiki Yamaji; Shoichiro Tsugane
Journal:  Int J Cancer       Date:  2015-08-13       Impact factor: 7.396

Review 2.  Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - "ABC method".

Authors:  Kazumasa Miki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2011       Impact factor: 3.493

Review 3.  Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis.

Authors:  Teruhiko Terasawa; Hiroshi Nishida; Katsuaki Kato; Isao Miyashiro; Takaki Yoshikawa; Reo Takaku; Chisato Hamashima
Journal:  PLoS One       Date:  2014-10-14       Impact factor: 3.240

4.  Combination of Helicobacter pylori Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study.

Authors:  Fumie Ikeda; Kentaro Shikata; Jun Hata; Masayo Fukuhara; Yoichiro Hirakawa; Tomoyuki Ohara; Naoko Mukai; Masaharu Nagata; Daigo Yoshida; Koji Yonemoto; Motohiro Esaki; Takanari Kitazono; Yutaka Kiyohara; Toshiharu Ninomiya
Journal:  J Epidemiol       Date:  2016-06-04       Impact factor: 3.211

  4 in total
  6 in total

1.  Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan.

Authors:  Shota Saito; Motoi Azumi; Yusuke Muneoka; Katsuhiko Nishino; Takashi Ishikawa; Yuichi Sato; Shuji Terai; Kouhei Akazawa
Journal:  Eur J Health Econ       Date:  2017-05-26

2.  Association between ALDH2 and ADH1B polymorphisms, alcohol drinking and gastric cancer: a replication and mediation analysis.

Authors:  Kuka Ishioka; Hiroyuki Masaoka; Hidemi Ito; Isao Oze; Seiji Ito; Masahiro Tajika; Yasuhiro Shimizu; Yasumasa Niwa; Shigeo Nakamura; Keitaro Matsuo
Journal:  Gastric Cancer       Date:  2018-04-03       Impact factor: 7.370

3.  Serum pepsinogen 1 and anti-Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males.

Authors:  M Song; M C Camargo; S J Weinstein; G Murphy; N D Freedman; J Koshiol; R Z Stolzenberg-Solomon; C C Abnet; S Männistö; D Albanes; C S Rabkin
Journal:  Aliment Pharmacol Ther       Date:  2017-12-15       Impact factor: 8.171

4.  Combined Gastric and Colorectal Cancer Screening-A New Strategy.

Authors:  Michael Selgrad; Jan Bornschein; Arne Kandulski; Jochen Weigt; Albert Roessner; Thomas Wex; Peter Malfertheiner
Journal:  Int J Mol Sci       Date:  2018-12-03       Impact factor: 5.923

5.  Human gastric cancer risk screening: From rat pepsinogen studies to the ABC method.

Authors:  Chie Furihata
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2021       Impact factor: 3.493

6.  Who Could Be Blamed in the Case of Discrepant Histology and Serology Results for Helicobacter pylori Detection?

Authors:  Sabine Skrebinska; Francis Megraud; Ilva Daugule; Daiga Santare; Sergejs Isajevs; Inta Liepniece-Karele; Inga Bogdanova; Dace Rudzite; Reinis Vangravs; Ilze Kikuste; Aigars Vanags; Ivars Tolmanis; Selga Savcenko; Chloé Alix; Rolando Herrero; Jin Young Park; Marcis Leja
Journal:  Diagnostics (Basel)       Date:  2022-01-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.